These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 30943145)

  • 21. Comparison of comorbidities and treatment between ankylosing spondylitis and non-radiographic axial spondyloarthritis in the United States.
    Zhao SS; Ermann J; Xu C; Lyu H; Tedeschi SK; Liao KP; Yoshida K; Moots RJ; Goodson NJ; Solomon DH
    Rheumatology (Oxford); 2019 Nov; 58(11):2025-2030. PubMed ID: 31081033
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rotation or change of biotherapy after TNF blocker treatment failure for axial spondyloarthritis: the ROC-SpA study, a randomised controlled study protocol.
    Dalix E; Marcelli C; Bejan-Angoulvant T; Finckh A; Rancon F; Akrour M; De Araujo L; Presles E; Marotte H;
    BMJ Open; 2024 Sep; 14(9):e087872. PubMed ID: 39260856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Have Therapeutics Enhanced Our Knowledge of Axial Spondyloarthritis?
    Harrison SR; Marzo-Ortega H
    Curr Rheumatol Rep; 2023 Mar; 25(3):56-67. PubMed ID: 36652160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of serious infections in biological treatment of patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
    Wang S; He Q; Shuai Z
    Clin Rheumatol; 2018 Feb; 37(2):439-450. PubMed ID: 29290076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Upadacitinib for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA).
    Fukui S; Kawaai S; Sawada H; Kishimoto M
    Expert Rev Clin Immunol; 2024 Feb; 20(2):141-153. PubMed ID: 37955181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extra-articular manifestations and burden of disease in patients with radiographic and non-radiographic axial spondyloarthritis.
    Erol K; Gok K; Cengiz G; Kilic G; Kilic E; Ozgocmen S
    Acta Reumatol Port; 2018; 43(1):32-39. PubMed ID: 29342471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prevalence and clinical characteristics of nonradiographic axial spondyloarthritis among patients with inflammatory back pain in rheumatology practices: a multinational, multicenter study.
    Burgos-Varga R; Wei JC; Rahman MU; Akkoc N; Haq SA; Hammoudeh M; Mahgoub E; Singh E; Llamado LJ; Shirazy K; Kotak S; Hammond C; Pedersen R; Shen Q; Vlahos B
    Arthritis Res Ther; 2016 Jun; 18(1):132. PubMed ID: 27267875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fatigue in Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Analysis from a Longitudinal Observation Cohort.
    Bedaiwi M; Sari I; Thavaneswaran A; Ayearst R; Haroon N; Inman RD
    J Rheumatol; 2015 Dec; 42(12):2354-60. PubMed ID: 26523020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment with tumor necrosis factor inhibitors in axial spondyloarthritis: comparison between private rheumatology practices and academic centers in a large observational cohort.
    Ciurea A; Weber U; Stekhoven D; Scherer A; Tamborrini G; Bernhard J; Toniolo M; Villiger PM; Zufferey P; Kissling RO; Michel BA; Exer P;
    J Rheumatol; 2015 Jan; 42(1):101-5. PubMed ID: 25362654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in pharmacotherapies for axial spondyloarthritis.
    Toussirot E
    Expert Opin Pharmacother; 2023; 24(13):1439-1448. PubMed ID: 37318776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis.
    Levitova A; Hulejova H; Spiritovic M; Pavelka K; Senolt L; Husakova M
    Arthritis Res Ther; 2016 Nov; 18(1):275. PubMed ID: 27887637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of Health Outcomes with Etanercept Treatment in Patients with Early Nonradiographic Axial Spondyloarthritis.
    Dougados M; Tsai WC; Saaibi DL; Bonin R; Bukowski J; Pedersen R; Vlahos B; Kotak S
    J Rheumatol; 2015 Oct; 42(10):1835-41. PubMed ID: 26276968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics.
    Sieper J; Rudwaleit M; Lenaerts J; Wollenhaupt J; Myasoutova L; Park SH; Song YW; Yao R; Huyck S; Govoni M; Chitkara D; Vastesaeger N
    Rheumatology (Oxford); 2016 Nov; 55(11):1946-1953. PubMed ID: 27411482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sex Differences in Time to Initiate Nonsteroidal Anti-Inflammatory Drugs or Biologic Disease-Modifying Antirheumatic Drugs Among Patients With Axial Spondyloarthritis.
    Shridharmurthy D; Lapane KL; Baek J; Nunes AP; Weisman MH; Kay J; Liu SH
    Arthritis Care Res (Hoboken); 2024 Aug; 76(8):1149-1161. PubMed ID: 38538532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update.
    Ramiro S; Nikiphorou E; Sepriano A; Ortolan A; Webers C; Baraliakos X; Landewé RBM; Van den Bosch FE; Boteva B; Bremander A; Carron P; Ciurea A; van Gaalen FA; Géher P; Gensler L; Hermann J; de Hooge M; Husakova M; Kiltz U; López-Medina C; Machado PM; Marzo-Ortega H; Molto A; Navarro-Compán V; Nissen MJ; Pimentel-Santos FM; Poddubnyy D; Proft F; Rudwaleit M; Telkman M; Zhao SS; Ziade N; van der Heijde D
    Ann Rheum Dis; 2023 Jan; 82(1):19-34. PubMed ID: 36270658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advances in treatment of axial spondyloarthritis are associated with improved patient outcomes: data from the Ankylosing Spondylitis Registry of Ireland (ASRI).
    Maguire S; Fitzgerald G; Gallagher P; O'Shea F
    Rheumatol Int; 2022 May; 42(5):831-838. PubMed ID: 35088133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using natural language processing to explore characteristics and management of patients with axial spondyloarthritis and psoriatic arthritis treated under real-world conditions in Spain: SpAINET study.
    Benavent D; Muñoz-Fernández S; De la Morena I; Fernández-Nebro A; Marín-Corral J; Castillo Rosa E; Taberna M; Sanabra C; Sastre C;
    Ther Adv Musculoskelet Dis; 2023; 15():1759720X231220818. PubMed ID: 38146537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study.
    Dougados M; Wood E; Combe B; Schaeverbeke T; Miceli-Richard C; Berenbaum F; Koppiker N; Dubanchet A; Logeart I
    Arthritis Res Ther; 2014 Nov; 16(6):481. PubMed ID: 25428762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discriminant validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis: a cohort study.
    Kilic E; Kilic G; Akgul O; Ozgocmen S
    Rheumatol Int; 2015 Jun; 35(6):981-9. PubMed ID: 25366469
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elevated faecal calprotectin is linked to worse disease status in axial spondyloarthritis: results from the SPARTAKUS cohort.
    Olofsson T; Lindqvist E; Mogard E; Andréasson K; Marsal J; Geijer M; Kristensen LE; Wallman JK
    Rheumatology (Oxford); 2019 Jul; 58(7):1176-1187. PubMed ID: 30649509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.